Company intelligence / Profile preview

QSAM Therapeutics

Austin, Texas, United States

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

QSAM developed CycloSam® (Samarium‑153 DOTMP), a novel targeted radiopharmaceutical designed to deliver the Samarium‑153 radioisotope directly to sites of primary or metastatic bone cancer. The company completed initial Phase I clinical studies focused on safety and early efficacy in both adult and pediatric patients with osteosarcoma or metastatic disease. The technology builds on prior FDA-approved products but uses an improved chelating agent for better targeting and reduced off-target toxicity. As of May 2024, the company was acquired by Telix Pharmaceuticals to integrate this asset into their oncology portfolio.

Therapeutic areas: Oncology
Modalities: therapeutic radiopharmaceuticalsradionuclide drug conjugates
Industry: Biotech

Drug pipeline

1 asset

CycloSam

Phase 1

Indications: Bone cancer, Bone metastases, Osteosarcoma

Partnerships

RLS Radiopharmacies/RLS Inc.: Clinical/commercial supply agreement for CycloSam® production/distribution in the U.S.University of Texas at Austin Nuclear Reactor Center – isotope production collaboration

Beyond the preview

Go deeper on QSAM Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QSAM Therapeutics.

Explore the full profile